GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neurogene Inc (NAS:NGNE) » Definitions » Total Stockholders Equity

Neurogene (Neurogene) Total Stockholders Equity : $170.78 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Neurogene Total Stockholders Equity?

Neurogene's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $170.78 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Neurogene's Book Value per Share for the quarter that ended in Mar. 2024 was $13.28. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Neurogene's Debt-to-Equity for the quarter that ended in Mar. 2024 was 0.09.

Neurogene Total Stockholders Equity Historical Data

The historical data trend for Neurogene's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurogene Total Stockholders Equity Chart

Neurogene Annual Data
Trend Dec21 Dec22 Dec23
Total Stockholders Equity
-91.88 -145.74 186.02

Neurogene Quarterly Data
Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Stockholders Equity Get a 7-Day Free Trial - -169.05 -183.21 186.02 170.78

Neurogene  (NAS:NGNE) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Neurogene's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(170.777-0)/12.861
=13.28

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Neurogene's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(3.143 + 12.552) / 170.777
=0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurogene Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Neurogene's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Neurogene (Neurogene) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neurogene Inc (NAS:NGNE) » Definitions » Total Stockholders Equity
Comparable Companies
Traded in Other Exchanges
N/A
Address
535 W 24th Street, 5th Floor, New York, NY, USA, 10011
Website
https://www.neurogene.com
Neurogene Inc is a clinical stage biotechnology company whose objective is to harness the power of gene therapy which is combined with its EXACT gene regulation technology to turn today's complex devastating neurological diseases into treatable conditions.

Neurogene (Neurogene) Headlines

From GuruFocus

Neurogene Announces Closing of Merger with Neoleukin Therapeutics and Concurrent Private Placement of $95 Million

By Business Wire • 12-19-2023

Neurogene Announces Business Update and 2024 Outlook

By Business Wire • 01-05-2024